Search Results

insitro, a machine learning-powered drug discovery and development company, today announced the appointment of S. Michael Rothenberg, M.D., Ph.D., as chief medical officer.

insitro, a machine learning-powered drug discovery and development company, today announced that Daphne Koller, Ph.D., founder and CEO, will present a company overview, including recent business and research highlights, at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:30 p.m. PT.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

insitro, a machine learning-driven drug discovery and development company, today announced the expansion of its leadership team with the appointments of several industry leaders.

As part of the collaboration, insitro will deploy its machine-learning capabilities on Genomics England’s histopathology images and accompanying genetic data to learn a multimodal representation that captures the fine grained semantic structure in this high-dimensional clinical data.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).

Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).

Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.